ADIAOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

Adia Med, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.13−0.01 (-7.14%)

Close on Oct 19, 2026

Market cap: $20.98M
P/E (TTM): –
Dividend yield: –

Adia Med, Inc. cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31
Depreciation & Amortization	0.00	0.00
Stock-Based Compensation	0.04	0.03
Change in Accounts Receivable	-0.03	0
Change in Accounts Payable	0.00	0.00
Change in Unearned Revenue	0.01	0
Operating Cash Flow	-0.18	-0.34
Capital Expenditures	-0.01	-0.02
Investing Cash Flow	-0.03	-0.03
Stock Issued	0.07	0.03
Financing Cash Flow	0.28	0.37
Net Change in Cash	0.07	0.01
Free Cash Flow	-0.19	-0.36
Income Taxes Paid	0	0
Interest Paid	0	0

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 27.4%
Operating margin: -52.3%
Net margin: -56.5%
Return on equity, FY2025: 340.7%

Financial strength

Current ratio: 0.32
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 12.1%

Valuation

P/E ratio: –
Price to sales: 29.95
Price to book: –
Dividend yield: –